Described herein are compositions for topical administration, to relieve psoriasis of the scalp. The compositions comprise a cannabinoid and at least one additional active ingredient. The additional active ingredient may be salicylic acid or coal tar. The compositions may be biphasic compositions comprising an aqueous phase and an oil-based phase. The two phases may be contained in a single container and mixed, for example, by shaking, before administration of the composition to the scalp of the patient.

Described herein are compositions for topical administration, to relieve psoriasis of the scalp. The compositions comprise a cannabinoid and at least one additional active ingredient. The additional active ingredient may be salicylic acid or coal tar. The compositions may be biphasic compositions comprising an aqueous phase and an oil-based phase. The two phases may be contained in a single container and mixed, for example, by shaking, before administration of the composition to the scalp of the patient.

Described herein are compositions for topical administration, to relieve psoriasis of the scalp. The compositions comprise a cannabinoid and at least one additional active ingredient. The additional active ingredient may be salicylic acid or coal tar. The compositions may be biphasic compositions comprising an aqueous phase and an oil-based phase. The two phases may be contained in a single container and mixed, for example, by shaking, before administration of the composition to the scalp of the patient.

Provided herein are methods and compositions for the treatment of cancer by modulating the microbiome to enhance the efficacy of immune checkpoint blockade. The microbiome may be modulated by the administration of butyrate and/or butyrate-producing bacteria. Also provided herein are methods of determining a response to an immune checkpoint inhibitor by identifying if a subject has a favorable microbial profile.

The present invention is a method and composition for the treatment of skin conditions where the epidermal barrier has decreased function such as when the patient is suffering from eczema, in particular, Atopic Dermatitis. Epidermal barrier function can be significantly improved and the extraction of epidermal lipids can be reduced by using formulations containing high Krafft temperature surfactants, preferably, anionic surfactants.

The present invention is a method and composition for the treatment of skin conditions where the epidermal barrier has decreased function such as when the patient is suffering from eczema, in particular, Atopic Dermatitis. Epidermal barrier function can be significantly improved and the extraction of epidermal lipids can be reduced by using formulations containing high Krafft temperature surfactants, preferably, anionic surfactants.

This invention provides a topical drug formulation and methods for the preparation thereof. This invention further provides the use of said drug formulation in pharmaceutical compositions and methods of treating mammals. This invention also provides the use of said drug formulation in pharmaceutical compositions for dermatological and transdermal applications. More specifically, this invention provides an aqueous-based drug formulation which has increased storage stability and controlled drug release upon application. The present application also describes materials and methods useful in creating such drug formulations.

This invention provides a topical drug formulation and methods for the preparation thereof. This invention further provides the use of said drug formulation in pharmaceutical compositions and methods of treating mammals. This invention also provides the use of said drug formulation in pharmaceutical compositions for dermatological and transdermal applications. More specifically, this invention provides an aqueous-based drug formulation which has increased storage stability and controlled drug release upon application. The present application also describes materials and methods useful in creating such drug formulations.

Compositions and methods for treating tar-responsive dermatological disorders are described. In particular, an anhydrous tar composition including a liquid wax and a therapeutically effective amount of tar in an anhydrous solvent, the composition being in liquid form at room temperature is described. The anhydrous tar composition can be topically applied to skin of a subject for treatment of tar-responsive dermatological disorders, such as psoriasis, eczema, atopic dermatitis, seborrheic dermatitis and pruritus.

Compositions and methods for treating tar-responsive dermatological disorders are described. In particular, an anhydrous tar composition including a liquid wax and a therapeutically effective amount of tar in an anhydrous solvent, the composition being in liquid form at room temperature is described. The anhydrous tar composition can be topically applied to skin of a subject for treatment of tar-responsive dermatological disorders, such as psoriasis, eczema, atopic dermatitis, seborrheic dermatitis and pruritus.